BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG

BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.

More: FinSMEs, Endpoints News, Fierce Biotech, BioSpace, American Chemical Society, GeekWire, WebProNews, BrainChild Bio, Inc.
Comments: Kyle LaHucik, Alex Philippidis

No comments yet.